These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 10220105)

  • 1. Memory assessment in studies of cognition-enhancing drugs for Alzheimer's disease.
    Simard M; van Reekum R
    Drugs Aging; 1999 Mar; 14(3):197-230. PubMed ID: 10220105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
    Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
    Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Global measures: utility in defining and measuring treatment response in dementia.
    Reisberg B
    Int Psychogeriatr; 2007 Jun; 19(3):421-56. PubMed ID: 17480241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Donepezil provides greater benefits in mild compared to moderate Alzheimer's disease: implications for early diagnosis and treatment.
    Molinuevo JL; Berthier ML; Rami L
    Arch Gerontol Geriatr; 2011; 52(1):18-22. PubMed ID: 19948364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and Prognostic Value of the Combination of Two Measures of Verbal Memory in Mild Cognitive Impairment due to Alzheimer's Disease.
    Sala I; Illán-Gala I; Alcolea D; Sánchez-Saudinós MB; Salgado SA; Morenas-Rodríguez E; Subirana A; Videla L; Clarimón J; Carmona-Iragui M; Ribosa-Nogué R; Blesa R; Fortea J; Lleó A
    J Alzheimers Dis; 2017; 58(3):909-918. PubMed ID: 28527215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice].
    Robert PH; Schuck S; Dubois B; Lépine JP; Gallarda T; Olié JP; Goni S; Troy S
    Encephale; 2003; 29(3 Pt 1):266-72. PubMed ID: 12876552
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific Verbal Memory Measures May Distinguish Alzheimer's Disease from Dementia with Lewy Bodies.
    Bussè C; Anselmi P; Pompanin S; Zorzi G; Fragiacomo F; Camporese G; Di Bernardo GA; Semenza C; Caffarra P; Cagnin A
    J Alzheimers Dis; 2017; 59(3):1009-1015. PubMed ID: 28697561
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical trials in predementia stages of Alzheimer disease.
    Pillai JA; Cummings JL
    Med Clin North Am; 2013 May; 97(3):439-57. PubMed ID: 23642580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Domain-specific improvement of cognition on memantine in patients with Alzheimer's disease treated with rivastigmine.
    Riepe MW; Adler G; Ibach B; Weinkauf B; Tracik F; Gunay I
    Dement Geriatr Cogn Disord; 2007; 23(5):301-6. PubMed ID: 17356273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognitive and anatomical correlates of anosognosia in amnestic mild cognitive impairment and early-stage Alzheimer's disease.
    Senturk G; Bilgic B; Arslan AB; Bayram A; Hanagasi H; Gurvit H; Emre M
    Int Psychogeriatr; 2017 Feb; 29(2):293-302. PubMed ID: 27780496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life and Utility Measurement in a Large Clinical Trial Sample of Patients with Mild to Moderate Alzheimer's Disease: Determinants and Level of Changes Observed.
    Lacey L; Bobula J; Rüdell K; Alvir J; Leibman C
    Value Health; 2015 Jul; 18(5):638-45. PubMed ID: 26297092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct neuroanatomical bases of episodic and semantic memory performance in Alzheimer's disease.
    Hirni DI; Kivisaari SL; Monsch AU; Taylor KI
    Neuropsychologia; 2013 Apr; 51(5):930-7. PubMed ID: 23369803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Behavioral outcomes in clinical trials for Alzheimer disease.
    Ferris SH; Mackell JA
    Alzheimer Dis Assoc Disord; 1997; 11 Suppl 4():S10-5. PubMed ID: 9339267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuropsychological differentiation between Alzheimer's disease and dementia with Lewy bodies in a memory clinic.
    Kawai Y; Miura R; Tsujimoto M; Sakurai T; Yamaoka A; Takeda A; Arahata Y; Washimi Y; Kachi T; Toba K
    Psychogeriatrics; 2013 Sep; 13(3):157-63. PubMed ID: 25913764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Declarative memory.
    Riedel WJ; Blokland A
    Handb Exp Pharmacol; 2015; 228():215-36. PubMed ID: 25977084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes in metabolite ratios after treatment with rivastigmine in Alzheimer's disease: a nonrandomised controlled trial with magnetic resonance spectroscopy.
    Modrego PJ; Pina MA; Fayed N; Díaz M
    CNS Drugs; 2006; 20(10):867-77. PubMed ID: 16999455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Free and Cued Selective Reminding Test is superior to the Wechsler Memory Scale in discriminating mild cognitive impairment from Alzheimer's disease.
    Lemos R; Cunha C; Marôco J; Afonso A; Simões MR; Santana I
    Geriatr Gerontol Int; 2015 Aug; 15(8):961-8. PubMed ID: 25243721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced semantic fluency as an additional screening tool for subjects with questionable dementia.
    Lam LC; Ho P; Lui VW; Tam CW
    Dement Geriatr Cogn Disord; 2006; 22(2):159-64. PubMed ID: 16837791
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.